Status:

COMPLETED

OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.

Lead Sponsor:

Centre Hospitalier Universitaire de Nice

Conditions:

Pituitary Adenoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The aim of the study is to assess accurancy of OCT angiography as a pronostic marker for patients undergoing neurosurgery for compressiver macroadenoma as compared with visual acuity, visual field and...

Eligibility Criteria

Inclusion

  • pituitary compressive adenoma (for experimental group)
  • pituitary non compressive adenoma

Exclusion

  • retinian disease
  • amblyopia
  • parkinson disease
  • pregnant woman

Key Trial Info

Start Date :

November 14 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 22 2023

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT04074642

Start Date

November 14 2019

End Date

February 22 2023

Last Update

November 18 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

CHU de NICE

Nice, France, 06000

2

Hôpital Pasteur 2 - Service d'Ophtalmologie

Nice, France, 06001

OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study. | DecenTrialz